These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 34479957)
41. High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer. Wei L; Zhu S; Li M; Li F; Wei F; Liu J; Ren X Front Immunol; 2018; 9():724. PubMed ID: 29719533 [TBL] [Abstract][Full Text] [Related]
42. Role of indoleamine 2,3-dioxygenase in acute myeloid leukemia. Sobash PT; Kolhe R; Karim NA; Guddati AK; Jillella A; Kota V Future Oncol; 2020 Dec; 16(36):3085-3094. PubMed ID: 32976029 [TBL] [Abstract][Full Text] [Related]
44. Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells. Sun J; Yu J; Li H; Yang L; Wei F; Yu W; Liu J; Ren X J Exp Clin Cancer Res; 2011 Sep; 30(1):82. PubMed ID: 21917155 [TBL] [Abstract][Full Text] [Related]
45. The Kynurenine/Tryptophan Ratio and Glioblastoma Patients Treated with Hsppc-96 Vaccine. Lenzen A; Zhai L; Lauing KL; Gritsina G; Ladomersky E; Genet M; James CD; Bloch O; Wainwright DA Immunotherapy (Los Angel); 2016 Sep; 2(3):. PubMed ID: 27819068 [TBL] [Abstract][Full Text] [Related]
46. Improved Radiosynthesis and Biological Evaluations of L- and D-1-[ Xin Y; Cai H Mol Imaging Biol; 2017 Aug; 19(4):589-598. PubMed ID: 27815661 [TBL] [Abstract][Full Text] [Related]
47. Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway. Li R; Li H; Sun Q; Liu L; Zhang C; Ren X Mol Immunol; 2017 Jan; 81():102-107. PubMed ID: 27930920 [TBL] [Abstract][Full Text] [Related]
48. Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. Monjazeb AM; Kent MS; Grossenbacher SK; Mall C; Zamora AE; Mirsoian A; Chen M; Kol A; Shiao SL; Reddy A; Perks JR; T N Culp W; Sparger EE; Canter RJ; Sckisel GD; Murphy WJ Clin Cancer Res; 2016 Sep; 22(17):4328-40. PubMed ID: 26979392 [TBL] [Abstract][Full Text] [Related]
49. Interleukin-6 and indoleamine-2,3-dioxygenase as potential adjuvant targets for Papillomavirus-related tumors immunotherapy. Pagni RL; Souza PDC; Pegoraro R; Porchia BFMM; da Silva JR; Aps LRMM; Silva MO; Rodrigues KB; Sales NS; Ferreira LCS; Moreno ACR Front Immunol; 2022; 13():1005937. PubMed ID: 36405719 [TBL] [Abstract][Full Text] [Related]
50. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. Yan Y; Zhang GX; Gran B; Fallarino F; Yu S; Li H; Cullimore ML; Rostami A; Xu H J Immunol; 2010 Nov; 185(10):5953-61. PubMed ID: 20944000 [TBL] [Abstract][Full Text] [Related]
51. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Brandacher G; Perathoner A; Ladurner R; Schneeberger S; Obrist P; Winkler C; Werner ER; Werner-Felmayer G; Weiss HG; Göbel G; Margreiter R; Königsrainer A; Fuchs D; Amberger A Clin Cancer Res; 2006 Feb; 12(4):1144-51. PubMed ID: 16489067 [TBL] [Abstract][Full Text] [Related]
52. Peripheral kynurenine/tryptophan ratio is not a reliable marker of systemic indoleamine 2,3-dioxygenase: A lesson drawn from patients on hemodialysis. Chen Y; Xie Z; Xiao C; Zhang M; Li Z; Xie J; Zhang Y; Zhao X; Zeng P; Mo L; Liang X; Shi W Oncotarget; 2017 Apr; 8(15):25261-25269. PubMed ID: 28445957 [TBL] [Abstract][Full Text] [Related]
53. Indoleamine 2,3-dioxygenase, by degrading L-tryptophan, enhances carnitine palmitoyltransferase I activity and fatty acid oxidation, and exerts fatty acid-dependent effects in human alloreactive CD4+ T-cells. Eleftheriadis T; Pissas G; Sounidaki M; Tsogka K; Antoniadis N; Antoniadi G; Liakopoulos V; Stefanidis I Int J Mol Med; 2016 Nov; 38(5):1605-1613. PubMed ID: 27667153 [TBL] [Abstract][Full Text] [Related]
54. Effect of Kidney-replenishing herb on the indoleamine 2,3-dioxygenase of human syncytiotrophoblasts cultured in vitro and the balance of helper T-cell cytokines. Li X; Gui S; Wang H Gynecol Endocrinol; 2007 Nov; 23(11):653-61. PubMed ID: 17999277 [TBL] [Abstract][Full Text] [Related]
55. IDO inhibits T-cell function through suppressing Vav1 expression and activation. Li R; Wei F; Yu J; Li H; Ren X; Hao X Cancer Biol Ther; 2009 Jul; 8(14):1402-8. PubMed ID: 19597340 [TBL] [Abstract][Full Text] [Related]
56. Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct. Söderlund J; Erhardt S; Kast RE J Neuroinflammation; 2010 Aug; 7():44. PubMed ID: 20691089 [TBL] [Abstract][Full Text] [Related]
57. Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO. Zhang A; Zheng Y; Que Z; Zhang L; Lin S; Le V; Liu J; Tian J J Cancer Res Clin Oncol; 2014 Nov; 140(11):1883-90. PubMed ID: 24980548 [TBL] [Abstract][Full Text] [Related]
58. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Riesenberg R; Weiler C; Spring O; Eder M; Buchner A; Popp T; Castro M; Kammerer R; Takikawa O; Hatz RA; Stief CG; Hofstetter A; Zimmermann W Clin Cancer Res; 2007 Dec; 13(23):6993-7002. PubMed ID: 18056175 [TBL] [Abstract][Full Text] [Related]
59. Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Jasperson LK; Bucher C; Panoskaltsis-Mortari A; Mellor AL; Munn DH; Blazar BR Blood; 2009 Dec; 114(24):5062-70. PubMed ID: 19828695 [TBL] [Abstract][Full Text] [Related]